Calix, Inc. CALX
33.84 USD +0.59 (+1.77%)
At closeNov 4, 2026, 4:00 PM EST
33.85 +0.01 +0.03%
After hours · Nov 4, 4:00 PM ET
32.87 Day range 34.38
32.35 52-week range 68.19
- YTD
- -36.07%
- 1 year
- -48.30%
Analyst view
Price target (mean) 62.33 +84.2% upside
Now 33.84
- Target (low)
- 52.00
- Target (mean)
- 62.33
- Target (high)
- 85.00
Ratings (0m) 7 6 buy · 1 hold · 0 sell
- Strong buy2
- Buy4
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.44527 | 0.37 – 0.42904 | 0.39 | +14.2% | 314.19M | +15.3% | 7 |
| Next quarter | 0.49 | 0.4069 – 0.53 | 0.39 | +25.6% | 318.90M | +13.9% | 7 |
| Current year | 1.72 | 1.64 – 1.78 | 1.35 | +27.5% | 1.19B | +18.9% | 7 |
| Next year | 2.29 | 1.90 – 2.54 | 1.72 | +33.2% | 1.37B | +15.6% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Nov 4, 2026 | Rosenblatt | Maintained | Buy | Buy |
| Jul 23, 2026 | Rosenblatt | Maintained | Buy | Buy |
| Jul 22, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Jul 21, 2026 | Northland Capital Markets | Upgrade | Market Perform | Outperform |
| Jul 21, 2026 | Rosenblatt | Maintained | Buy | Buy |
| Jun 10, 2026 | Rosenblatt | Maintained | Buy | Buy |
| Apr 23, 2026 | Rosenblatt | Maintained | Buy | Buy |
| Apr 23, 2026 | Needham | Maintained | Buy | Buy |
| Apr 22, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Apr 22, 2026 | Rosenblatt | Maintained | Buy | Buy |
| Apr 16, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Mar 31, 2026 | Rosenblatt | Maintained | Buy | Buy |
| Jan 30, 2026 | Rosenblatt | Maintained | Buy | Buy |
| Jan 30, 2026 | Needham | Maintained | Buy | Buy |
| Jan 27, 2026 | Rosenblatt | Maintained | Buy | Buy |
| Jan 15, 2026 | JP Morgan | Upgrade | Neutral | Overweight |
| Nov 24, 2025 | Needham | Reiterated | Buy | Buy |
| Oct 31, 2025 | JP Morgan | Maintained | Neutral | Neutral |
| Oct 31, 2025 | Rosenblatt | Maintained | Buy | Buy |
| Oct 31, 2025 | Needham | Maintained | Buy | Buy |
| Sep 15, 2025 | Roth Capital | Maintained | Buy | Buy |
| Jul 23, 2025 | Rosenblatt | Maintained | Buy | Buy |
| Jul 22, 2025 | Needham | Maintained | Buy | Buy |
| Jul 22, 2025 | Rosenblatt | Maintained | Buy | Buy |
| Jul 17, 2025 | JP Morgan | Maintained | Neutral | Neutral |
| Jul 15, 2025 | Rosenblatt | Maintained | Buy | Buy |
| Jul 8, 2025 | Wolfe Research | Initiated | — | Peer Perform |
| Jun 12, 2025 | Rosenblatt | Maintained | Buy | Buy |
| Apr 23, 2025 | JP Morgan | Maintained | Neutral | Neutral |
